Research programme: hyperbranched polyglycerol-based therapeutics - Sitka Biopharma

Drug Profile

Research programme: hyperbranched polyglycerol-based therapeutics - Sitka Biopharma

Alternative Names: HPG-docetaxel; STK 01

Latest Information Update: 10 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sitka Biopharma
  • Class Glycerols
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bladder cancer

Most Recent Events

  • 26 Jun 2017 Sitka Biopharma, Cancer Research UK and Cancer Research technology agree to co-develop STK 01 for Bladder Cancer
  • 26 Jun 2017 Sitka Biopharma plans a phase I trial for Bladder cancer in UK (Intravesicular instillation)
  • 03 Dec 2013 Preclinical trials in Bladder cancer in Canada (Intravesicular instillation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top